IDH-mutant glioma
Trial arms side by side.
One row is one arm. A blank cell is n/r. A hazard ratio appears only when the source states it. Weeks stay weeks, and a patient count stays a count.
ClassNone selected
No arms selected. Choose a drug, an arm, or a preset.
7 of 9 arms with a reported figure. Choose arms to narrow the chart.
| Arm | Reported safety |
|---|---|
| Vorasidenib 40 mg | grade 3 or higher adverse events: 22.8%, NEJM 2023 (placebo 13.5%)grade 3 or 4 ALT increase (pooled): 9%, labelgrade 3 or 4 AST increase (pooled): 4.8%, labelpermanent discontinuation for ALT elevation: 2.9%, label |
| Vorasidenib Phase 1 doses | n/r |
| Safusidenib (AB-218, DS-1001) 250 mg | n/r |
| Olutasidenib 150 mg | grade 3 to 4 ALT increase: 12%grade 3 to 4 AST increase: 12% |
| Ivosidenib Phase 1 doses | n/r |
| IDH1-VAC (IDH1 R132H Peptide Vaccine) not stated in source | n/r |
| Olaparib 300 mg | n/r |
A count stays a count. This page does not turn a count into a percent.
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.